ArticleFrontiers in oncology2020

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

Rafael Rosell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.